Venetoclax en combinació amb rituximab en la leucèmia limfocítica crònica després de tractament previ
Abstract
Chronic lymphocytic leukemia (CLL) is the most common leukemia in our environment in adulthood and accounts for 25-50% of all leukemias. The median age at diagnosis is 72 years and only 10% of patients are <55 years. It has a prevalence of 3.5 cases / 10,000 inhabitants and an annual incidence of 4-5 new cases / 100,000 inhabitants. The incidence increases to> 30 cases / 100,000 / year in patients> 70 years. It affects men more often than women (2:1).
Keywords
Chronic lymphocytic leukemia; Rituximab; Venetoclax; Treatment
Bibliographic citation
Programa d'Harmonització Farmacoterapèutica. Venetoclax en combinació amb rituximab en la leucèmia limfocítica crònica després de tractament previ. Barcelona: Servei Català de la Salut; 2021.
Audience
Professionals
Use this identifier for quote and/or link this document
https://hdl.handle.net/11351/6081This item appears in following collections
The following license files are associated with this item: